Last reviewed · How we verify
SanaCutan Basiscreme
SanaCutan Basiscreme is a Small molecule drug developed by Infectopharm Arzneimittel GmbH. It is currently in Phase 3 development for Dry skin and skin barrier dysfunction, Irritated or damaged skin conditions.
SanaCutan Basiscreme is a topical emollient and skin barrier repair cream that hydrates and protects damaged or irritated skin.
SanaCutan Basiscreme is a moisturizer used in a clinical trial to prevent symptoms of atopic dermatitis in early childhood. It has been studied in infants and newborns with atopic dermatitis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SanaCutan Basiscreme |
|---|---|
| Sponsor | Infectopharm Arzneimittel GmbH |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
This is a basic skincare formulation designed to restore and maintain the skin barrier function through occlusive and humectant ingredients. It provides symptomatic relief for dry, irritated, or compromised skin by reducing transepidermal water loss and supporting natural skin healing processes.
Approved indications
- Dry skin and skin barrier dysfunction
- Irritated or damaged skin conditions
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SanaCutan Basiscreme CI brief — competitive landscape report
- SanaCutan Basiscreme updates RSS · CI watch RSS
- Infectopharm Arzneimittel GmbH portfolio CI
Frequently asked questions about SanaCutan Basiscreme
What is SanaCutan Basiscreme?
How does SanaCutan Basiscreme work?
What is SanaCutan Basiscreme used for?
Who makes SanaCutan Basiscreme?
What development phase is SanaCutan Basiscreme in?
Related
- Manufacturer: Infectopharm Arzneimittel GmbH — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Dry skin and skin barrier dysfunction
- Indication: Drugs for Irritated or damaged skin conditions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing